Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:SMMT
- CUSIP: N/A
- Web: www.summitplc.com
Capitalization:- Market Cap: $157.07 million
- Outstanding Shares: 12,381,000
Average Prices:- 50 Day Moving Avg: $12.79
- 200 Day Moving Avg: $11.91
- 52 Week Range: $5.31 - $19.75
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.73
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $5.34 million
- Price / Sales: 28.31
- Book Value: ($0.85) per share
- Price / Book: -14.36
Profitability:- EBIDTA: ($32,150,000.00)
- Net Margins: -507.08%
- Return on Equity: -30,092.17%
- Return on Assets: -66.82%
Debt:- Current Ratio: 2.59%
- Quick Ratio: 2.58%
Misc:- Average Volume: 10,219 shs.
- Beta: 0.38
- Short Ratio: 3.59
Frequently Asked Questions for Summit Therapeutics PLC (NASDAQ:SMMT)
What is Summit Therapeutics PLC's stock symbol?
Summit Therapeutics PLC trades on the NASDAQ under the ticker symbol "SMMT."
When will Summit Therapeutics PLC make its next earnings announcement?
Where is Summit Therapeutics PLC's stock going? Where will Summit Therapeutics PLC's stock price be in 2017?
5 brokerages have issued 1-year price objectives for Summit Therapeutics PLC's stock. Their predictions range from $24.00 to $30.00. On average, they expect Summit Therapeutics PLC's share price to reach $27.40 in the next twelve months. View Analyst Ratings for Summit Therapeutics PLC.
Who are some of Summit Therapeutics PLC's key competitors?
Some companies that are related to Summit Therapeutics PLC include Corbus Pharmaceuticals Holdings (CRBP), BioTime (BTX), Rigel Pharmaceuticals (RIGL), CymaBay Therapeutics (CBAY), Merus N.V. (MRUS), Oxford BioMedica plc (OXB), Minerva Neurosciences (NERV), Bellicum Pharmaceuticals (BLCM), Tocagen (TOCA), Circassia Pharmaceuticals PLC (CIR), DURECT Corporation (DRRX), Catalyst Pharmaceuticals (CPRX), ObsEva SA (OBSV), uniQure N.V. (QURE), Ardelyx (ARDX), Pieris Pharmaceuticals (PIRS), Chimerix (CMRX) and Immune Design Corp. (IMDZ).
Who are Summit Therapeutics PLC's key executives?
Summit Therapeutics PLC's management team includes the folowing people:
- Glyn Edwards, Chief Executive Officer, Executive Director
- Erik Ostrowski, Chief Financial Officer
- David Roblin, Chief Operating Officer, President - Research and Development
- Ralf H. Rosskamp M.D., Chief Medical Officer
- Frank Murdoch Armstrong, Non-Executive Chairman of the Board
- Valerie L. Andrews, Non-Executive Director
- Stephen J. Davies, Non-Executive Director
- Barry J. Price Ph.D., Non-Executive Director
- David Wurzer CPA, Non-Executive Director
When did Summit Therapeutics PLC IPO?
(SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.
Who owns Summit Therapeutics PLC stock?
Summit Therapeutics PLC's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include AXA (2.32%), First Eagle Investment Management LLC (1.41%), Sphera Funds Management LTD. (1.15%), Granite Point Capital Management L.P. (0.95%) and Acadian Asset Management LLC (0.10%). View Institutional Ownership Trends for Summit Therapeutics PLC.
Who sold Summit Therapeutics PLC stock? Who is selling Summit Therapeutics PLC stock?
Who bought Summit Therapeutics PLC stock? Who is buying Summit Therapeutics PLC stock?
How do I buy Summit Therapeutics PLC stock?
Shares of Summit Therapeutics PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Summit Therapeutics PLC's stock price today?
One share of Summit Therapeutics PLC stock can currently be purchased for approximately $12.21.
MarketBeat Community Rating for Summit Therapeutics PLC (NASDAQ SMMT)MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Summit Therapeutics PLC (NASDAQ:SMMT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $27.40 (124.41% upside) |
Analysts' Ratings History for Summit Therapeutics PLC (NASDAQ:SMMT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/22/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $24.00 | Low |  |
| 6/16/2017 | Canaccord Genuity | Reiterated Rating | Buy | $28.00 | Low | |
| 11/16/2016 | Royal Bank Of Canada | Boost Price Target | Outperform | $26.00 -> $29.00 | N/A | |
| 10/4/2016 | Needham & Company LLC | Boost Price Target | Buy | $22.00 -> $30.00 | N/A | |
| 9/16/2016 | HC Wainwright | Initiated Coverage | Buy | $26.00 | N/A | |
| 6/21/2016 | Janney Montgomery Scott | Initiated Coverage | Buy | | N/A | |
(Data available from 8/20/2015 forward)
Earnings History for Summit Therapeutics PLC (NASDAQ:SMMT)Earnings History by Quarter for Summit Therapeutics PLC (NASDAQ SMMT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 9/14/2017 | | | | | | | | |
| 8/27/2015 | Q215 | ($0.06) | ($0.55) | $0.39 million | $0.67 million | View | Listen | |
| 6/11/2015 | Q115 | ($0.06) | ($0.45) | $0.39 million | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Summit Therapeutics PLC (NASDAQ:SMMT)2017 EPS Consensus Estimate: ($1.92)
2018 EPS Consensus Estimate: ($0.98)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 1 | ($0.78) | ($0.78) | ($0.78) |
| Q3 2017 | 1 | ($0.64) | ($0.64) | ($0.64) |
| Q4 2017 | 1 | ($0.50) | ($0.50) | ($0.50) |
| Q1 2018 | 1 | ($0.65) | ($0.65) | ($0.65) |
| Q2 2018 | 1 | $1.15 | $1.15 | $1.15 |
| Q3 2018 | 1 | ($0.71) | ($0.71) | ($0.71) |
| Q4 2018 | 1 | ($0.77) | ($0.77) | ($0.77) |
(Data provided by Zacks Investment Research)
Dividend History for Summit Therapeutics PLC (NASDAQ:SMMT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Summit Therapeutics PLC (NASDAQ:SMMT)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Summit Therapeutics PLC (NASDAQ:SMMT)
Latest Headlines for Summit Therapeutics PLC (NASDAQ:SMMT)
| Source: |
|
Summit Therapeutics PLC (SMMT) Chart for Sunday, August, 20, 2017
